No supplier or customer ties in NTRB's filings yet. The map draws only what companies disclose to the SEC; ties named in other companies' filings join as the graph reads them.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
Nothing on the wire mentions NTRB yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How NTRB has moved on past release days vs its typical ±4.0% day, and how often it closed up. Computed from daily closes — not a forecast.